Linezolid is safe on platelet count for AML patients during myelosuppression after consolidation chemotherapy.
De ZhouTing ShiShuqi ZhaoJingjing ZhuLixia ZhuXiudi YangWanzhuo XieXiujin YePublished in: Journal of clinical pharmacy and therapeutics (2020)
This retrospective clinical study suggests that it is safe to manage AML patients in complete remission during myelosuppression after standard consolidation chemotherapy with idarubicin and cytarabine, with about 7 days of linezolid therapy.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- stem cells
- locally advanced
- cross sectional
- staphylococcus aureus
- patient reported outcomes
- allogeneic hematopoietic stem cell transplantation
- disease activity
- ulcerative colitis